Effects on coagulation of a synthetic heparan mimetic given intraperitoneally or orally

Journal of Biomedical Materials Research - Part A

Volumn 83, Issue 4, 2007, Pages 1024-1031

  Charef, Said ^a   Petit, Emmanuel ^b   Barritault, Denis ^b   Courty, José ^a   Caruelle, Jean Pierre ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b SAS   (France)

Author keywords

Coagulation; Oral anticoagulant; Synthetic heparan mimetic

Indexed keywords

HEPARAN SULFATE-MIMETIC POLYMERS; PROTHROMBIN; SYNTHETIC HEPARAN MIMETICS; TISSUE REPAIR;

BIOACTIVITY; BIOASSAY; COAGULATION; COMPLEXATION; POLYSACCHARIDES; TISSUE ENGINEERING;

BIOMIMETICS;

ANTICOAGULANT AGENT; OTR 4120; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD CLOTTING TIME; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBIN TIME; THROMBOCYTE COUNT;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEPARIN; MICE; MICE, INBRED C57BL; MOLECULAR MIMICRY;

EID: 36849038980     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31385     Document Type: Article

References (28)

1. Meddahi A, Caruelle JP, Gold L, Rosso Y, Barritault D. New concepts in tissue repair: Skin as an example. Diabetes Metab 1996;22:274-278.
2. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP. Heparan-like molecules induce the repair of skull defects. Bone 1995;17:499-506.
3. Escartin Q, Lallam-Laroye C, Baroukh B, Morvan FO, Caruelle JP, Godeau G, Barritault D, Saffar JL. A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers. Faseb J 2003;17:644-651.
4. Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J. A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. Faseb J 1999;13:761-766.
5. Yamauchi H, Desgranges P, Lecerf L, Papy-Garcia D, Tournaire MC, Moczar M, Loisance D, Barritault D. New agents for the treatment of infarcted myocardium. FASEB J 2000;14:2133-2134.
6. Ledoux D, Papy-Garcia D, Escartin Q, Sagot MA, Cao Y, Barritault D, Courtois J, Hornebeck W, Caruelle JP. Human plasmin enzymatic activity is inhibited by chemically modified dextrans. J Biol Chem 2000;275:29383-29390.
7. Ledoux D, Merciris D, Barritault D, Caruelle JP. Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G. FEBS Lett 2003;537:23-29.
8. Meddahi A, Lemdjabar H, Caruelle JP, Barritault D, Hornebeck W. FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int J Biol Macromol 1996;18:141-145.
9. Meddahi A, Bree F, Papy-Garcia D, Gautron J, Barritault D, Caruelle JP. Pharmacological studies of RGTA(H), a heparan sulfate mimetic polymer, efficient on muscle regeneration. J Biomed Mater Res 2002;62:525-531.
10. Tagesson C, Sjodahl R, Thoren B. Passage of molecules through the wall of the gastrointestinal tract. I. A simple experimental model. Scand J Gastroenterol 1978;13:519-524.
11. Wray W, Boulikas T, Wray VP, Hancock R. Silver staining of proteins in Polyacrylamide gels. Anal Biochem 1981;118:197-203.
12. Mahooti S, Graesser D, Patil S, Newman P, Duncan G, Mak T, Madri JA. PECAM-1 (CD31) expression modulates bleeding time in vivo. Am J Pathol 2000;157:75-81.
13. Mehvar R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J Control Release 2000;69:1-25.
14. Mauray S, De Raucourt E, Chaubet F, Maiga-Revel O, Sternberg C, Fischer AM. Comparative anticoagulant activity and influence on thrombin generation of dextran derivatives and of a fucoidan fraction. J Biomater Sci Polym Ed 1998;9:373-387.
15. Yamagishi R, Niwa M, Kondo S, Sakuragawa N, Koide T. Purification and biological property of heparin cofactor II. Activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans. Thromb Res 1984;36:633-642.
16. Logeart-Avramoglou D, Jozefonvicz J. Carboxymethyl benzylamide sulfonate dextrans (CMDBS), a family of biospecific polymers endowed with numerous biological properties: A review. J Biomed Mater Res 1999;48:578-590.
17. Petit E, Papy-Garcia D, Muller G, Courtois B, Caruelle JP, Courtois J. Controlled sulfatation of natural anionic bacterial polysaccharides can yield agents with specific regenerating activity in vivo. Biomacromolecules 2004;5:445-452.
18. Bode W, Turk D, Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1992;1:426-471.
19. Olson ST, Halvorson HR, Bjork I. Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. J Biol Chem 1991;266:6342-6352.
20. Scatena R. Bivalirudin: A new generation antithrombotic drug. Expert Opin Investig Drugs 2000;9:1119-1127.
21. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101:171-181.
22. Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, Kogan PW, Kogan TP, McKinney AA, Schwarz R. Jr. Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997;23:503-516.
23. Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004;38:99-109.
24. Beeler D, Rosenberg R, Jordan R. Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem 1979;254:2902-2913.
25. Maaroufi RM, Jozefowicz M, Tapon-Bretaudiere J, Jozefonvicz J, Fischer AM. Mechanism of thrombin inhibition by heparin cofactor II in the presence of dermatan sulphates, native or oversulphated, and a heparin-like dextran derivative. Biomaterials 1997;18:359-366.
26. Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998;6 (Suppl A):31-36.
27. Nickel JC. Interstitial cystitis. Etiology, diagnosis, and treatment. Can Fam Physician 2000;46:2430-2434.2437-2440.
28. Hiebert LM, Wice SM, Ping T. Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route. Biomed Pharmacother 2004;58:372-380.